Level of CSF CXCL10 is highly elevated and decreased after steroid therapy in patients with autoimmune glial fibrillary acidic protein astrocytopathy

To examine the chemokine profile in the cerebrospinal fluid (CSF) of patients with glial fibrillary acidic protein astrocytopathy (GFAP‐A), central nervous system immune‐related adverse event (CNS‐irAE), neurosarcoidosis (NS), neuromyelitis optica spectrum disorders (NMOSD), multiple sclerosis (MS), and human T‐cell leukemia virus‐1 (HTLV‐1)‐associated myelopathy (HAM).

[1]  Chinmoy Patra,et al.  Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review , 2022, Frontiers in Cell and Developmental Biology.

[2]  Y. Long,et al.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: To Identify Its Diagnosis, Management and Prognosis (GFAP-AID) Registry: Study Protocol for an Ambispective, Multicenter Registry in China , 2022, Neuropsychiatric disease and treatment.

[3]  P. Gallo,et al.  Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid , 2022, Frontiers in Immunology.

[4]  T. Shimohata,et al.  Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy , 2022, Brain sciences.

[5]  D. Karussis,et al.  Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis , 2022, Stem cells translational medicine.

[6]  N. Araya,et al.  Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P) , 2022, Viruses.

[7]  A. Kakita,et al.  Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis , 2021, Journal of Neuroimmunology.

[8]  T. Gardin,et al.  The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events , 2021, Neurology.

[9]  G. Gigli,et al.  Neurologic Adverse Events of Immune Checkpoint Inhibitors , 2021, Neurology.

[10]  M. Taheri,et al.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis , 2021, Metabolic Brain Disease.

[11]  A. Maghazachi,et al.  Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis , 2020, Journal of inflammation research.

[12]  Yu Peng,et al.  The CSF Levels of Neutrophil‐Related Chemokines in Patients with Neuromyelitis Optica , 2020, Annals of clinical and translational neurology.

[13]  Chun-Hong Shen,et al.  Autoimmune glial fibrillary acidic protein astrocytopathy , 2020 .

[14]  E. Inoue,et al.  Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[15]  Y. Hayashi,et al.  Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications , 2019, Journal of Neuroimmunology.

[16]  N. Araya,et al.  Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis , 2019, Front. Microbiol..

[17]  Y. Hayashi,et al.  Clinical characteristics of autoimmune GFAP astrocytopathy , 2019, Journal of Neuroimmunology.

[18]  S. Chieffi,et al.  Mini-Mental State Examination: new normative values on subjects in Southern Italy , 2019, Aging Clinical and Experimental Research.

[19]  A. McKeon,et al.  Autoimmune glial fibrillary acidic protein astrocytopathy , 2019, Current opinion in neurology.

[20]  Y. Long,et al.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the Literature , 2018, Front. Immunol..

[21]  Yang Xie,et al.  Immune dysregulation in cancer patients developing immune-related adverse events , 2018, British Journal of Cancer.

[22]  Y. Long,et al.  Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study , 2018, European journal of neurology.

[23]  Y. Long,et al.  Treatment of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: Follow-Up in 7 Cases , 2017, Neuroimmunomodulation.

[24]  S. Cuzzubbo,et al.  Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.

[25]  B. Weinshenker,et al.  Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients , 2017, Annals of neurology.

[26]  V. Lennon,et al.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. , 2016, JAMA neurology.

[27]  Takahiko Ueno,et al.  CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis , 2013, PLoS neglected tropical diseases.

[28]  P. Middleton.  Practical use of the Glasgow Coma Scale; a comprehensive narrative review of GCS methodology. , 2012, Australasian emergency nursing journal : AENJ.

[29]  J. Swieten.  Interobserver Agreement for the Assessment of Handicap in Stroke Patients , 2005 .

[30]  D. Royall,et al.  The FAB: A frontal assessment battery at bedside , 2001, Neurology.

[31]  A. V. van Oosterhout,et al.  Pharmacologic modulation of Th1- and Th2-associated lymphokine production. , 1993, Life sciences.

[32]  K. Kawakami,et al.  Differences between T helper cell type I (Th1) and Th2 cell lines in signalling pathways for induction of contact‐dependent T cell help , 1992, European journal of immunology.

[33]  A. Kelso,et al.  Heterogeneity in Lymphokine Profiles of CD4+ and CD8+ T Cells and Clones Activated in vivo and in vitro , 1991, Immunological reviews.

[34]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[35]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[36]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[37]  B. Jennett,et al.  Assessment of coma and impaired consciousness. A practical scale. , 1974, Lancet.